Results randomized trial idarubicin cytosine arabinoside daunorubicin cytosine arabinoside adult patients myelogenous leukemia idarubicin IDR new anthracycline differs parent compound deletion methoxy group position chromophore ring minor structural modification results lipophilic compound unique metabolite prolonged plasma half-life vitro vivo antileukemia activity activity acute myelogenous leukemia AML consecutive adult patients ages disease single institution study IDR combination cytosine arabinoside Ara-C standard therapy daunorubicin DNR Ara-C trial O'Brien-Fleming multiple design periodic inspection data specific patient accession points accrual patients arm analysis patients IDR/Ara-C superior response standard therapy patients complete remission former arm patients latter Logistic regression analysis factors complete response treatment IDR/Ara-C significant advantage patients high initial white blood cell count treatment DNR/Ara-C degree marrow aplasia arm nonhematologic toxicity Overall survival patients IDR/Ara-C arm months months DNR/Ara-C arm median follow-up years IDR/Ara-C standard therapy DNR/Ara-C adult patients age AML 